secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001654954-25-007893
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M
----------------------------------------------------------------------------

- No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.
- Expected operating loss of ~$1.3M, improved from ~$2.2M loss in Q2 2024.
- As of June 30, 2025: cash and equivalents $1.8M; total assets $2.6M; working capital $1.2M.
- Firm filed S-1 registration statement to offer shares and warrants in a public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/0001654954-25-007893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-007893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer